Shoupeng Lai

572 total citations
17 papers, 481 citations indexed

About

Shoupeng Lai is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Shoupeng Lai has authored 17 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Oncology. Recurrent topics in Shoupeng Lai's work include Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (3 papers) and Virus-based gene therapy research (2 papers). Shoupeng Lai is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (3 papers) and Virus-based gene therapy research (2 papers). Shoupeng Lai collaborates with scholars based in United States and China. Shoupeng Lai's co-authors include John M. Ward, Heven Sze, Anton Wellstein, Anna T. Riegel, Frank Czubayko, Anke M. Schulte, Armin Kurtz, Imara Y. Perera, Xiangming Fang and Yan Lou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shoupeng Lai

13 papers receiving 465 citations

Peers

Countries citing papers authored by Shoupeng Lai

Since Specialization

Citations

This map shows the geographic impact of Shoupeng Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shoupeng Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shoupeng Lai more than expected).

Fields of papers citing papers by Shoupeng Lai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shoupeng Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shoupeng Lai. The network helps show where Shoupeng Lai may publish in the future.

Co-authorship network of co-authors of Shoupeng Lai

This figure shows the co-authorship network connecting the top 25 collaborators of Shoupeng Lai. A scholar is included among the top collaborators of Shoupeng Lai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shoupeng Lai. Shoupeng Lai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Abstract 7323: LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of relapsed/refractory multiple myeloma 2025 ·Cancer Research ·(unknown), Xiao Huang, (unknown), Xiaoya Liu, Min Chen, (unknown), Guojin Wu, (unknown), (unknown), Hong Ling, Shoupeng Lai, Xiaoqiang Kang, (unknown)	0
2	Abstract 2934: Novel hydrophilic CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical xenograft models 2025 ·Cancer Research ·Yang Ye, (unknown), (unknown), (unknown), Wanting Wang, Tingting Li, Chao Ni, Chao‐Hsien Chu, (unknown), (unknown), (unknown), Yue Zhao, Xiao Huang, (unknown), Shoupeng Lai, Xiaoqiang Kang, Hong Ling	0
3	Lbl-043, a Novel LILRB4xCD3 T Cell Engager, for the Treatment of Relapsed/Refractory Multiple Myeloma 2024 ·Blood ·(unknown), Xiao Huang, (unknown), Xiaoya Liu, Mei Chen, (unknown), (unknown), Guojin Wu, (unknown), (unknown), (unknown), Shengli Cai, Shoupeng Lai, Xiaoqiang Kang, Hong Ling	0
4	Abstract 1867: LBL-049: A novel neutralizing antibody against GDF15 for the treatment of cachexia 2024 ·Cancer Research ·Baohui Wang, Xiao Huang, (unknown), (unknown), (unknown), Fengxia Li, Jing Guan, (unknown), Guojin Wu, Xiaoxiao Liu, (unknown), Shoupeng Lai, Xiaoqiang Kang, Hong Ling	2
5	Abstract 2965: LBL-033, a novel bispecific antibody targeting MUC16 and CD3, for the treatment of tumors over-expressing MUC16 2023 ·Cancer Research ·(unknown), Xiao Huang, (unknown), (unknown), Min Chen, Huan Lin, Jing Guan, (unknown), (unknown), Baohui Wang, Guojin Wu, Shoupeng Lai, Xiaoqiang Kang, Hong Ling	0
6	Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma 2023 ·Blood ·Baohui Wang, Xiao Huang, (unknown), (unknown), Hongyan Shang, (unknown), Guojin Wu, Min Chen, Hailin Wang, Peng Zhang, (unknown), (unknown), (unknown), Shengli Cai, Shoupeng Lai, Xiaoqiang Kang, Hong Ling	4
7	841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells 2023 ·SHILAP Revista de lepidopterología ·Baohui Wang, Hailin Wang, Tingting Li, (unknown), Xiao Huang, Huan Lin, (unknown), (unknown), Peng Zhang, Jing Guan, Guojin Wu, (unknown), Shoupeng Lai, Xiaoqiang Kang, Hong Ling	1
8	Abstract 5523: LBL-019, a novel anti-TNFR2 antibody, shows a potent anti-tumor efficacy in a mouse MC38 model 2022 ·Cancer Research ·Huan Lin, Xiao Huang, (unknown), (unknown), Peng Zhang, (unknown), Jing Guan, Shoupeng Lai, Xiaoqiang Kang, Hong Ling	2
9	Abstract 1791: LBL-015, a novel anti-PD-1 fused with TGF-βRII, shows a great anti-tumor activity in a mouse MC38 model 2021 ·Cancer Research ·Xiao Huang, (unknown), (unknown), Huan Lin, Jing Guan, Shoupeng Lai, Xiaoqiang Kang, Hong Ling	3
10	Abstract 1838: LBL-024, an anti-PD-L1 and 4-1BB bispecific antibody with highly differentiated binding affinity, shows anti-tumor efficacy in a mouse tumor model 2021 ·Cancer Research ·Xiao Huang, (unknown), (unknown), Huan Lin, Jing Guan, Shoupeng Lai, Xiaoqiang Kang, Hong Ling	1
11	The HVJ-Envelope as an Innovative Vector System for Cardiovascular Disease 2004 ·Current Gene Therapy ·Hitoshi Kotani, Toshihiro Nakajima, Shoupeng Lai, Ryuichi Morishita, Yasufumi Kaneda	8
12	Complementary adenoviral vectors for oncolysis 1999 ·Cancer Gene Therapy ·Ramón Alemany, Shoupeng Lai, Yan Lou, (unknown), Xiangming Fang, Weiwei Zhang	48
13	Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus 1996 ·Proceedings of the National Academy of Sciences ·Anke M. Schulte, Shoupeng Lai, Armin Kurtz, Frank Czubayko, Anna T. Riegel, Anton Wellstein	173
14	An additional 5'-upstream exon exists in the human pleiotrophin-encoding gene 1995 ·Gene ·Shoupeng Lai, Anke M. Schulte, Anton Wellstein, Anna T. Riegel	6
15	Vacuolar H+-translocating ATPases from plants: Structure, function, and isoforms 1992 ·Journal of Bioenergetics and Biomembranes ·Heven Sze, John M. Ward, Shoupeng Lai	172
16	Structure of the human heparin-binding growth factor gene pleiotrophin 1992 ·Biochemical and Biophysical Research Communications ·Shoupeng Lai, Frank Czubayko, Anna T. Riegel, Anton Wellstein	15
17	Vacuolar-type H+-translocating ATPases IN plant endomembranes: subunit organization and multigene families 1992 ·Journal of Experimental Biology ·Heven Sze, John M. Ward, Shoupeng Lai, Imara Y. Perera	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact